Evidence map›Paper›PMID 40980882›Full record

ArticlemBio2025

TLR9 signaling requires ligand-induced phosphorylation of two specific tyrosine residues by EGFR and Syk.

Manoj Veleeparambil, Chenyao Wang, Patricia M Kessler, Pracheta Sengupta, Santanu Das, Ritu Chakravarti, Belinda Willard, Ganes C Sen, Saurabh Chattopadhyay

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Manoj VeleeparambilDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Chenyao WangDepartment of Immunity and Inflammation, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Patricia M KesslerDepartment of Immunity and Inflammation, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Pracheta SenguptaDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Santanu DasDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Ritu ChakravartiDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Belinda WillardDepartment of Immunity and Inflammation, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ganes C SenDepartment of Immunity and Inflammation, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-9692-0631
Saurabh ChattopadhyayDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky, USA.ORCID 0000-0002-2930-1523

Funding

TELOMERASE INACTIVATION BY RNASE L SIGNALS CELL DEATHP01CA062220 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, XIAOXIA · 1994 to 2020
$35.6M
ANTIVIRAL ACTIONS OF INTERFERONSR01CA068782 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SEN, GANES C. · 1995 to 2020
$7.6M
Transcriptional and non-transcriptional functions of IRF3 in ALDR01AA027456 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI LAURA E. NAGY · 2019 to 2026
$3.5M
Anti-inflammatory functions for non-transcriptional IRF3R01AI155545 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI Saurabh Chattopadhyay · 2021 to 2026
$2.2M
Novel antiviral mechanisms of the interferon systemR01AI165521 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI Saurabh Chattopadhyay · 2022 to 2026
$1.7M
Determining role of 14-3-3zeta in IL-17A signalingR01AI184880 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI CHAKRAVARTI, RITU · 2024 to 2025
$1.6M
High-End Instrumentation (HEI) Grant Program (S10)S10OD023436 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2017 to 2017
$873k
NCI NIH HHS P01 CA062220NCI NIH HHS R01 CA068782NIAAA NIH HHS R01 AA027456NIAID NIH HHS R01 AI155545NIAID NIH HHS R01 AI165521NIAID NIH HHS R01 AI184880NIH HHS S10 OD023436
6 · The paper itself

Abstract

Toll-like receptors (TLRs) are transmembrane proteins that recognize microbial components or cellular danger signals and activate intracellular signaling pathways, leading to induction of anti-microbial and inflammatory genes. Inactive TLRs require ligand-induced activation to recruit adaptor proteins, e.g., MyD88, to trigger the synthesis of cytokines and interferons. TLR9 is an endosomal membrane-bound protein that binds to CpG-containing microbial DNA or endogenous signals from dead cells or tissue damage. We showed that TLR9 activation requires EGFR, a tyrosine (Tyr) kinase, which interacts with and phosphorylates the cytoplasmic domain of TLR9. Blocking EGFR activity pharmacologically, or knocking out EGFR gene in myeloid cells, suppressed lethal TLR9-induced hepatotoxicity. Here, we reveal that TLR9 required two Src family of kinases, Syk and Lyn, which, together with EGFR, led to phosphorylation and activation of TLR9. Lack of either of these kinases inhibited TLR9-MyD88 interaction, thereby inhibiting TLR9-mediated gene induction. Unlike EGFR, which constitutively binds TLR9, activated Syk interacted with TLR9 in a CpG-dependent manner. Activated Syk interacted with TLR9 and was critical for activating TLR9-bound EGFR. Quantitative mass spectrometric analyses revealed that TLR9 was phosphorylated sequentially on Tyr IMPORTANCE: Toll-like receptors (TLRs) are critical components of cellular innate immune responses to microbial infection or tissue damage. TLRs are transmembrane proteins that require activation to mount a successful host response; TLR mutations are associated with human diseases. TLR ligands are also used as vaccine adjuvants to amplify the inflammatory responses of the host, activation of TLRs, and their regulation are essential. Here, we report the molecular mechanisms of TLR9 activation by tyrosine phosphorylation of its cytoplasmic domain. TLR9 interacts with EGFR and Syk, the tyrosine kinases, which phosphorylate two specific tyrosine residues on the TLR9 cytoplasmic domain. Mutation of these tyrosine residues or deficiency of these tyrosine kinases leads to impaired TLR9 signaling. Therefore, our results elucidate the early events of TLR9 signaling with implications in inflammatory diseases.

Indexed as

ErbB ReceptorsSignal TransductionSyk KinaseToll-Like Receptor 9TyrosineAnimalsHumansLigandsMicePhosphorylationsrc-Family KinasesErbB ReceptorsLigandslyn protein-tyrosine kinasesrc-Family KinasesSyk KinaseSyk protein, mouseTlr9 protein, mouseToll-Like Receptor 9Tyrosinecell signalingEGFRinnate imunityLynSykTLR9toll-like receptorstyrosine phosphorylation

Identifiers

PMID40980882
PMCPMC12607686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.